Evidence library
A plain-language guide to the published BPC-157 research referenced across this site, with direct links to every paper.
Start here
These papers synthesize multiple experiments. They are useful for orientation, but they are not new controlled trials.
This narrative review surveys experimental work on gastric protection, wound healing, blood vessels, ischemia-reperfusion injury, and muscle wasting. It presents a broad proposed organ-protection framework, drawing mainly from preclinical models rather than a new human or canine trial.
Gut and Liver, 2020 · PMID 31158953
View paper on PubMedThis review brings together animal findings from skin wounds, burns, fistulas, tendon, ligament, muscle, bone, nerve, spinal cord, cornea, and blood-vessel models. Its central theme is that vascular responses may contribute to the reported healing effects, but the article itself does not report a new controlled trial.
Frontiers in Pharmacology, 2021 · PMID 34267654
View paper on PubMedThis systematic review included 36 studies: 35 preclinical studies and one small retrospective human study. The authors reported promising animal findings across muscle, tendon, ligament, and bone injury models, while emphasizing the lack of clinical safety data and the low level of available human evidence.
HSS Journal, 2025 · PMID 40756949
View paper on PubMedAnimal evidence
Primary studies that tested BPC-157 in controlled injury models.
Researchers compared cell-culture work with crushed muscle and transected muscle and tendon models in rats. BPC-157 did not show direct angiogenic activity in cultured cells, while treated animals showed vascular changes associated with more organized healing and increased VEGF expression.
Journal of Physiology and Pharmacology, 2009 · PMID 20388964
View paper on PubMedAfter Achilles tendon transection, treated rats were assessed over 14 days using functional, biomechanical, microscopic, and macroscopic measures. The treatment groups showed higher functional scores and failure loads, more organized collagen-related healing, and smaller tendon defects than saline controls.
Journal of Orthopaedic Research, 2003 · PMID 14554208
View paper on PubMedRats with surgically transected medial collateral ligaments received BPC-157 by intraperitoneal, oral, or topical routes and were followed for up to 90 days. Across routes, the authors reported improvements in functional, biomechanical, macroscopic, and histological healing measures.
Journal of Orthopaedic Research, 2010 · PMID 20225319
View paper on PubMedResearchers created radial bone defects that remained incompletely healed in saline controls over six weeks. Several local or intramuscular BPC-157 regimens increased radiographic and histomorphometric signs of healing, with some outcomes compared against bone marrow or cortical graft treatment.
Bone, 1999 · PMID 10071911
View paper on PubMedIn a gastrocnemius muscle crush model, rats received local or intraperitoneal BPC-157 immediately after injury and during a 14-day follow-up. Treated animals showed less hematoma and edema, improved histology and enzyme markers, and better functional recovery than controls.
Surgery Today, 2008 · PMID 18668315
View paper on PubMedAnimal evidence
Representative studies outside the musculoskeletal literature.
Topical BPC-157 was tested in a rat alkali-burn model alongside human endothelial-cell experiments. Treated wounds showed faster closure, greater granulation, re-epithelialization, collagen deposition, and VEGF expression; cell experiments also reported increased migration and vascular-tube formation.
Drug Design, Development and Therapy, 2015 · PMID 25995620
View paper on PubMedIn rat models of interrupted colonic blood flow, reperfusion, and obstruction, local BPC-157 treatment was associated with rapid reappearance of collateral vessels, smaller pale areas, preserved mucosal folds, and normalized oxidative-stress and nitric-oxide measures.
World Journal of Gastroenterology, 2017 · PMID 29358856
View paper on PubMedRats received a single intraperitoneal dose 10 minutes after a compression injury and were followed for up to 360 days. Treated animals showed better tail motor function and less spasticity, along with reduced microscopic signs of axonal loss, demyelination, edema, and cyst formation.
Journal of Orthopaedic Surgery and Research, 2019 · PMID 31266512
View paper on PubMedPreclinical profile
Animal studies examining tolerance, distribution, metabolism, and clearance.
Single-dose and repeated-dose studies were conducted in mice, rats, rabbits, and dogs. The authors reported no serious test-related toxicity, mild local irritation, no detected genetic or embryo-fetal toxicity, and a reversible creatinine decrease at the highest dog dose.
Regulatory Toxicology and Pharmacology, 2020 · PMID 32334036
View paper on PubMedAfter intravenous and intramuscular dosing, the reported prototype half-life was under 30 minutes in rats and beagle dogs. Intramuscular bioavailability was estimated at 14 to 19 percent in rats and 45 to 51 percent in dogs, with urinary and biliary excretion after metabolism into smaller peptide fragments.
Frontiers in Pharmacology, 2022 · PMID 36588717
View paper on PubMedGlossary
Last literature review: August 2026
Return to homepage